Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.

Clark, James M; Kelley, Benjamin; Titze, Jill; Fung, Henry; Maciejewski, John; Nathan, Sunita; Rich, Elizabeth; Basu, Sanjib; Kaufman, Howard L

Clark, James M; Kelley, Benjamin; Titze, Jill; Fung, Henry; Maciejewski, John; Nathan, Sunita; Rich, Elizabeth; Basu, Sanjib; Kaufman, Howard L.

Affiliation

Clark JM; Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA.

Oncology ; 84(2): 123-6, 2013.

Article in En | MEDLINE | ID: mdl-23235386

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Renal Cell/drug therapy; Interleukin-2/therapeutic use; Kidney Neoplasms/drug therapy; Melanoma/drug therapy; Aged; Carcinoma, Renal Cell/mortality; Carcinoma, Renal Cell/pathology; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Kidney Neoplasms/mortality; Kidney Neoplasms/pathology; Male; Melanoma/mortality; Melanoma/secondary; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Interleukin-2 / Kidney Neoplasms / Melanoma / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Oncology Year: 2013 Document type: Article Affiliation country: United States Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google